Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis

BACKGROUND AND OBJECTIVES: Evidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe and able to induce humoral and cellular responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes-Leiva, David, López-Contreras, Joaquín, Moga, Esther, Pla-Juncà, Francesc, Lynton-Pons, Elionor, Rojas-Garcia, Ricardo, Turon-Sans, Janina, Querol, Luis, Olive, Montse, Álvarez-Velasco, Rodrigo, Caballero-Ávila, Marta, Carbayo, Álvaro, Vesperinas-Castro, Ana, Domingo, Pere, Illa, Isabel, Gallardo, Eduard, Cortés-Vicente, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219516/
https://www.ncbi.nlm.nih.gov/pubmed/35728947
http://dx.doi.org/10.1212/NXI.0000000000200002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219516/
https://www.ncbi.nlm.nih.gov/pubmed/35728947
http://dx.doi.org/10.1212/NXI.0000000000200002

Ejemplares similares